XORTX Therapeutics (XRTX) Other financing activities (2020 - 2026)
XORTX Therapeutics (XRTX) posted Other financing activities of -$81968.0 for Q1 2026, up 69.78% on a QoQ basis from -$271208.0 in Q3 2025, and down 258.74% year-over-year from $51637.4 in Q1 2025.
XORTX Therapeutics (XRTX) Other financing activities (2020 - 2026) Analysis & Trends
XORTX Therapeutics' Other financing activities history runs 6 years deep, the most recent figure standing at -$81968.0 for Q1 2026.
- Quarterly Other financing activities fell 258.74% year-over-year to -$81968.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$372240.0 (down 16.16% YoY) and the FY2022 annual result came in at $3.9 million, up 5736.55% from the prior year.
- Other financing activities was -$81968.0 for Q1 2026 at XORTX Therapeutics, up from -$271208.0 in the prior quarter.
- Across five years, Other financing activities topped out at $3785.0 in Q2 2025 and bottomed at -$297607.0 in Q1 2024.
- A 4-year average of -$112676.2 and a median of -$52408.5 in 2025 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2024 — Other financing activities sank 4692.38% — and 2025, when it jumped 92.32%.
- XORTX Therapeutics' Other financing activities stood at -$6210.0 in 2023, then sank by 4692.38% to -$297607.0 in 2024, then grew by 8.87% to -$271208.0 in 2025, then soared by 69.78% to -$81968.0 in 2026.
- Business Quant data shows XRTX's Other financing activities at -$81968.0 in Q1 2026, -$271208.0 in Q3 2025, and $3785.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | XORTX Therapeutics | 20.40 Mn | 20.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -81,968.00 |
| Mar 31, 2026 | -81,968.00 |
| Sep 30, 2025 | -271,208.00 |
| Sep 30, 2025 | -271,208.00 |
| Jun 30, 2025 | 3,785.00 |
| Jun 30, 2025 | 3,785.00 |
| Mar 31, 2025 | -22,849.00 |
| Mar 31, 2025 | -22,849.00 |
| Mar 31, 2024 | -297,607.00 |
| Mar 31, 2024 | -297,607.00 |
| Mar 31, 2023 | -6,210.00 |
| Mar 31, 2023 | -6,210.00 |
| Dec 31, 2021 | -1.12 Mn |
| Dec 31, 2021 | -1.12 Mn |
| Sep 30, 2021 | 378,200.00 |
| Sep 30, 2021 | 378,200.00 |
| Mar 31, 2021 | 801,165.25 |
| Mar 31, 2021 | 801,165.25 |
| Dec 31, 2020 | 1.26 Mn |
| Dec 31, 2020 | 1.26 Mn |